Lawsuits Can Kill Vaccines

Legal pressure and media amplification can collapse demand for an approved vaccine, prompting manufacturers to withdraw products even when regulators judge benefits to exceed risks. That commercial exit can leave populations vulnerable and deter future investment in vaccines for emerging or climate‑driven diseases. — This frames litigation and reputational risk as a structural barrier to vaccine supply and public‑health preparedness, suggesting policy levers (liability rules, communication strategies, genetic‑screening policy) matter as much as science.